NLS Pharmaceutics AG Cash Flow Conversion Efficiency
NLS Pharmaceutics AG cash flow conversion efficiency. Based on the latest financial reports, NLS Pharmaceutics AG (NLSP) has a cash flow conversion efficiency ratio of -0.719x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.07 Million) by net assets ($2.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NLS Pharmaceutics AG (2017–2024)
Cash flow conversion efficiency of NLS Pharmaceutics AG from 2017 to 2024. This chart illustrates how NLS Pharmaceutics AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for NLS Pharmaceutics AG for real-time trading data and today's change.
NLS Pharmaceutics AG Cash Flow Conversion Ratio Explained
NLS Pharmaceutics AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NLS Pharmaceutics AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NLS Pharmaceutics AG ranked by their cash flow conversion efficiency. Also see NLS Pharmaceutics AG market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tourn International AB
ST:TOURN
|
0.052x |
|
YouGov plc
LSE:YOU
|
0.045x |
|
PLENUM AG NA O.N.
F:PLEK
|
N/A |
|
Blue Coast Hotels Limited
NSE:BLUECOAST
|
0.010x |
|
Wi2Wi Corporation
V:YTY
|
-0.128x |
|
BACTECH ENVIRONMENT.CORP.
F:0BT1
|
N/A |
|
Frp Advisory Group Plc
LSE:FRP
|
0.275x |
|
Madoro Metals Corp
V:MDM
|
-0.030x |
Annual Cash Flow Conversion Efficiency for NLS Pharmaceutics AG (2017–2024)
The table below shows the annual cash flow conversion efficiency of NLS Pharmaceutics AG from 2017 to 2024. Review cash generation quality of NLS Pharmaceutics AG to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.41 Million | $-4.27 Million | -3.035x | -376.81% |
| 2023-12-31 | $-8.83 Million | $-9.68 Million | 1.096x | +125.92% |
| 2022-12-31 | $3.28 Million | $-13.88 Million | -4.230x | +84.64% |
| 2021-12-31 | $542.39K | $-14.94 Million | -27.538x | -34018.81% |
| 2020-12-31 | $-8.98 Million | $-729.39K | 0.081x | +163.67% |
| 2019-12-31 | $-6.17 Million | $-190.01K | 0.031x | -90.07% |
| 2018-12-31 | $-8.81 Million | $-2.73 Million | 0.310x | -55.95% |
| 2017-12-31 | $-7.72 Million | $-5.43 Million | 0.704x | -- |
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity … Read more